Clinical Trial NU 12H06
- A Randomized Phase I Dose-Escalation Trial of Carfilzomib with and without Romidepsin in Cutaneous T-Cell Lymphoma
- Principal Investigator
- Barbara Pro
- Status: CLOSED
- Study Type: Therapeutic, Treatment
- Protocol No:.NU 12H06
- The purpose of this study is to determine the highest tolerated dose of carfilzomib that can be given by itself or with romidepsin and to evaluate its effects, good and/or bad in treating cutaneous T-cell lymphoma (CTCL).
- Romidepsin is approved by the Food and Drug Administration (FDA) for treatment of CTCL. Romidepsin is a histone deacetylase inhibitor. These types of drugs alter some proteins that are associated with cancerous cells. Carfilzomib is FDA approved for treatment of multiple myeloma but not for CTCL. Carfilzomib is a proteasome inhibitor. A proteasome is a protein found within cells that has the important role of identifying and marking damaged proteins that are needed to be destroyed by the cell for survival. This research is being done to see if carfilzomib will improve the treatment of CTCL.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have cutaneous T-cell lymphoma.
- Description of Treatment
- Participants will be randomly assigned (by chance, like a coin toss) to receive either carfilzomib by itself or carfilzomib plus romidepsin. The dose of carfilzomib given is dependent upon the time of enrollment into the study. Both groups will receive 2 cycles of treatment. Each cycle consists of 28 days. After cycle 2, participants will be assessed for disease response and will either continue on in the study or be taken off the study treatment. Participants who continue in the study will be reassessed every 2 cycles there after. Treatment may continue for participants until the study doctor decides it is in their best interest to be removed from the study.
- Clinical Trials Recruitment Nurse
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Barbara Pro
- Phase II Study of Romidepsin Plus Lenalidomide for Patients with Previously Untreated PTCL
- A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
last updated: 23-May-17 09:09 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.